Organon & Co.
OGN- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821825
In the last 90 days, Organon & Co. insiders filed 0 open-market purchases and 1 sale; 636 institutions reported holding it in 13F filings for Q2 2026, worth $2.92B in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Organon & Co. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 855 | 14 | 793 | −48 |
| Shares | 194.2M | 70.7K | 194.8M | +637.4K (+0.3%) |
| Value | $6.56B | $2.55M | $4.57B | −$1.99B (−30.3%) |
14 institutions that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (77)
Institutions that held Organon & Co. at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (125)
Institutions that held Organon & Co. at the end of Q2 2022 and filed for Q3 2022 without it.
Showing the largest 100 of 125 by value.
Not filed for Q3 2022 yet (14)
Institutions that held Organon & Co. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Bruderman Asset Management, LLC | 17,570 | $593.0K |
| Sciencast Management LP | 17,574 | $559.0K |
| Advisor Partners LLC | 15,322 | $517.0K |
| B. Riley Wealth Management, Inc. | 7,734 | $461.0K |
| Exane Derivatives | 7,781 | $262.6K |
| Cordasco Financial Network | 2,342 | $79.0K |
| Brewin Dolphin Ltd | 1,327 | $45.0K |
| Private Capital Group, LLC | 342 | $12.0K |
| Fieldpoint Private Securities, LLC | 215 | $7.00K |
| Brewin Dolphin Wealth Management Ltd | 178 | $6.00K |
| Urban Wealth Management, LLC | 99 | $3.00K |
| US Asset Management LLC | 81 | $3.00K |
| Lake Point Wealth Management | 52 | $2.00K |
| Bivin & Associates, Inc. | 60 | $2.00K |